Coccidioidomycosis

Clinics in Dermatology

Volumn 30, Issue 6, 2012, Pages 573-591

  Welsh, Oliverio ^a   Vera Cabrera, Lucio ^a   Rendon, Adrian ^a   Gonzalez, Gloria ^b   Bonifaz, Alexandro ^c  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c Hospital General   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTACID AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FUNGUS VACCINE; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE; VORICONAZOLE;

ABDOMINAL PAIN; ANTIBODY DETECTION; ARTICLE; BONE INFECTION; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CLINICAL FEATURE; COCCIDIOIDOMYCOSIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FUNGAL EXAMINATION; FUNGAL MENINGITIS; FUNGAL VIRULENCE; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; IMMUNOPATHOGENESIS; INFECTION PREVENTION; LABORATORY TEST; LIVER CELL DAMAGE; LIVER TOXICITY; LUNG DISEASE; NAUSEA; NEPHROTOXICITY; PHOTOSENSITIVITY; PREGNANCY DISORDER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SKIN INFECTION; TAXONOMIC IDENTIFICATION; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT INFECTION; VISUAL DISORDER; VOMITING;

EID: 84867585709     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.01.003     Document Type: Note

References (87)

1. Fisher F.S., Bultman M.W., Johnson S.M., et al. Coccidioides niches and habitat parameters in the southwestern United States. Ann N Y Acad Sci 2007, 1111:47-72.
2. Gonzalez-Ochoa A. La coccidioidomicosis en Mexico. Rev Invest Salud Publ (Mex) 1966, 26:245-262.
3. Poncio Mendes R., Negroni R., Bonifaz A., et al. New aspects of some endemic mycoses. Med Mycol 2000, 38(Suppl 1):237-241.
4. Laniado-Laborin R. Expanding understanding of epidemiology of coccidioidomycosis in the western hemisphere. Ann N Y Acad Sci 2007, 1111:19-34.
5. Wanke B., Lazera M., Monterio P.C., et al. Investigation of an outbreak of endemic coccidioidomycosis in Brazil's nortern state of Piaui with a review of the occurrence and distribution of Coccidioides immitis in three other Brazilian states. Mycopathologia 1999, 148:57-67.
6. Bonifaz A., Vázquez-González D., Perusquía-Ortiz A.M. Endemic systemic mycoses: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Dtsch Dermatol Ges 2011, 9:705-714.
7. Posadas A. Un Nuevo Caso de Micosis Fungoidea con Psorospermias. An d Circ Med Argent 1892, 15:585-597.
8. Wernicke R. Ueber einen Protozoenbefund bei Mycosis fungoides. Centralbl f Bakt 1892, 12:859-861.
9. Deresinski S.C. History of coccidioidomycosis: dust to dust. Coccidioidomycosis: a text 1980, 1-20. Plenum Medical Book Co., New York. D.A. Stevens (Ed.).
10. Negroni R. Evolución de los conocimientos sobre aspectos clínico-epidemiológicos de la Coccidioidomycosis en las Américas. Rev Argent Microbiol 2008, 40:246-256.
11. Ophuls W., Moffitt H.C. A new pathogenic mould (formerly described as a protozoon: Coccidioides immitis pyogenes). Philadelphia Med J 1900, 5:1471-1472.
12. Ophüls W. Further observations on a pathogenic mould formerly described as a protozoon (coccidioides immitis, coccidioides pyogenes). J Exp Med 1905, 6:443-485.
13. Centers for Disease Control and Prevention (CDC) Increase in Coccidioidomycosis-California, 2000-2007. MMWR Morb Mortal Wkly Rep 2009, 58:105-109.
14. Galgiani J.N., Ampel N.M., Blair J.E., et al. Coccidioidomycosis. Clin Infect Dis 2005, 41:1217-1223.
15. Fisher M.C., Koening G.L., White T.J., et al. Molecular and phenotipic description of Coccidioides posadasii sp. Nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002, 94:73-84.
16. Castañón-Olivares L.R., Laniado-Laborín R., Concepcion T., et al. Clinical comparison of two Mexican coccidioidins. Mycopathologia 2010, 169:427-430.
17. U.S.Department of Health and Human Services Biosafety in microbiological and biomedical laboratories 2007, U.S. Government Printing Office, Washington, DC. 5th ed.
18. de Aguiar Cordeiro R., Nogueira Brilhante R.S., Gadelha Rocha M.F., et al. Rapid diagnosis of coccidioidomycosis by nested PCR assay of sputum. Clin Microbiol Infect 2007, 13:449-451.
19. Bialek R., Kern J., Herrmann T., et al. PCR assays for identification of Coccidioides posadasii based on the nucleotide sequence of the antigen 2/proline-rich antigen. J Clin Microbiol 2004, 42:778-783.
20. Kohne D.E., Steigerwalt A.G., Brenner D.J. Nucleic acid probe specific for members of the genus Legionella. Legionella. Proc 2nd International Symposium 1984, 107-108. American Society for Microbiology, Washington, DC. C. Thornsberry, A. Ballows, W. Freeley (Eds.).
21. Rohrbough J.G., Galgiani J.N., Wysocki V.H. The application of proteomic techniques to fungal protein identification and quantification. Ann N Y Acad Sci 2007, 1111:133-146.
22. Ampel N.M., Hector R.F., Lindan C.P., et al. An archived lot of coccidioidin induces specific coccidioidal delayed-type hypersensitivity and correlates with in vitro assays of coccidioidal cellular immune response. Mycopathologia 2006, 161:67-72.
23. Smith C.E., Beard R. Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health 1946, 36:1394-1402.
24. Kirkland T.N., Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis 1996, 2:192-199.
25. Ampel N.M., Ryan KJ Carry P.J., et al. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in patients and a review of the literature. Medicine (Balt) 1986, 65:312-321.
26. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004, 50:1959-1966.
27. Hernandez J.L., Echevarria S., Garcia-Valtuille A., et al. Atypical coccidioidomycosis in an AIDS patient succesfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 1997, 16:592-594.
28. Binnicker M.J., Buckwalter S.P., Eisberner J.J., et al. Detection of Coccidioides species in clinical specimens by real-time PCR. J Clin Microbiol 2007, 45:173-178.
29. Galgiani J.N., Dugger K.O., Ampel N.M., et al. Extraction of serologic and delayed hypersensitivity antigens from spherules of Coccidioides immitis. Diagn Microbiol Infect Dis 1988, 11:65-80.
30. Geijtenbeek T.B., van Vliet S.J., Engering A., et al. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004, 22:33-54.
31. Ampel N.M. The complex immunology of human coccidioidomycosis. Ann N Y Acad Sci 2007, 1111:245-258.
32. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
33. Parish J.M., Blair J.E. Coccidioidomycosis. Mayo Clin Proc 2008, 83:343-348. [quiz 348-9].
34. Chiller T.M., Galgiani J.N., Stevens D.A. Coccidioidomycosis. Infect Dis Clin North Am 2003, 17:41-57.
35. Arsura E.L., Kilgore W.B., Ratnayake S.N. Erythema nodosum in pregnant patients with coccidioidomycosis. Clin Infect Dis 1998, 27:1201-1203.
36. Werner S.B. Coccidioidomycosis misdiagnosed as contact dermatitis. Calif Med 1972, 117:59-61.
37. DiCaudo D.J., Yiannias J.A., Laman S.D., et al. The exanthem of acute pulmonary coccidioidomycosis: clinical and histopathologic features of 3 cases and review of the literature. Arch Dermatol 2006, 142:744-746.
38. Dresinski S.C. Coccioioidomycosis of bones and joints. Coccidioidomycosis: a text 1980, 195-209. Plenum Publishing Corp, New York. D. Stevens (Ed.).
39. Igcr M. Coccidioidal osteomyelitis. Coccidioidomycosis: current clinical and diagnostic status 1977, 177-190. Symposia Specialists, Miami. L. Ajello (Ed.).
40. Dalinka M.K., Dinnenberg S., Greendyk W.H., et al. Roentgenographic features of osseous coccidioidomycosis and differential diagnosis. J Bone Joint Surg Am 1971, 53:1157-1164.
41. Johnson R.H., Einstein H.E. Coccidioidal meningitis. Clin Infect Dis 2006, 42:103-107.
42. Williams P.L. Vasculitic complications associated with coccidioidal meningitis. Semin Respir Infect 2001, 16:270-279.
43. Gagliani J.N. Opthalmic coccidioidomycosis. Coccidioidomycosis: a text 1980, 231-236. Plenum Publishing Corp, New York. D. Stevens (Ed.).
44. Petersen E.A. Genitourinary coccidioidomycosis. Coccidioidomycosis: a text 1980, 225-228. Plenum Publishing Corp, New York. D. Stevens (Ed.).
45. Homans J.D., Spencer L. Itraconazole treatment of nonmeningeal coccidioidomycosis in children: two case reports and review of the literature. Pediatr Infect Dis J 2010, 29:65-67.
46. Lavetter A. Coccidioidomycosis in Pediatrics. Coccidioidomycosis: a text 1980, 245-247. Plenum Publishing Corp, New York. D. Stevens (Ed.).
47. Spinello I.M., Johnson R.H., Baqi S. Coccidioidomycosis and pregnancy: a review. Ann N Y Acad Sci 2007, 1111:358-364.
48. Levine H.B., Miller R.L., Smith C.E. Influence of vaccination on respiratory coccidiodial disease in cynomolgus monkeys. J Immunol 1962, 89:242-251.
49. Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis 1993, 148:656-660.
50. Johnson S.M., Lerche N.W., Pappagianis D., et al. Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). Ann N Y Acad Sci 2007, 1111:290-300.
51. Schmelzer L.L., Tabershaw I.R. Exposure factors in occupational coccidioidomycosis. Am J Public Health Nations Health 1968, 58:107-113.
52. Park B.J., Sigel K., Vaz V., et al. An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis 2005, 191:1981-1987.
53. Winn W.A. The use of amphotericin B in the treatment of coccidioidal disease. Am J Med 1959, 27:617-635.
54. Groll A.H., Walsh T.J. Polyene antifungal agents. Fungal diseases of the lung 2000, 271-277. Lippincott Williams & Wilkins, Philadelphia. 3rd ed. G.A. Sarosi, S.F. Davies (Eds.).
55. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996, 9:512-531.
56. Sau K., Mambula S.S., Latz E., et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003, 278:37561-37568.
57. Clemons K.V., Ranney D.F., Stevens D.A. A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes. Curr Opin Investig Drugs 2001, 2:480-487.
58. Antony S., Dominguez D.C., Sotelo E. Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis. J Natl Med Assoc 2003, 95:982-985.
59. González G.M., Tijerina R., Najvar L.K., et al. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 2004, 48:2140-2143.
60. Ostrosky-Zeichner L., Marr K.A., Rex J.H., et al. Amphotericin B: time for a new "gold standard.". Clin Infect Dis 2003, 37:415-425.
61. Stevens D. Miconazole in the treatment of systemic fungal infections. Am Rev Respir Dis 1977, 116:801-806.
62. Welsh O., González J.G., Diaz M., et al. Therapeutic evaluation of ketoconazole in patients with coccidioidomycosis. Rev Infect Dis 1980, 2:651-655.
63. Graybill J.R., Lundberg D., Donovan W., et al. Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients. Rev Infect Dis 1980, 2:661-673.
64. Catanzaro A., Einstein H., Levine B., et al. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med 1982, 96:436-440.
65. Prentice A.G., Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005, 56(Suppl 1):i17-22.
66. Catanzaro A., Galgiani J.N., Levine B.E., et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med 1995, 98:249-256.
67. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993, 29:S37-41.
68. Galgiani J.N., Catanzaro A., Cloud G.A., et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000, 133:676-686.
69. Dewsnup D.H., Galgiani J.N., Graybill J.R., et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?. Ann Intern Med 1996, 124:305-310.
70. Limper A.H., Knox K.S., Sarosi G.A., et al. American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011, 183:96-128.
71. Greer N.D. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007, 20:188-196.
72. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004, 58:612-624.
73. Rachwalski E.J., Wieczorkiewicz J.T., Scheetz M.H. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008, 42:1429-1438.
74. Anstead G.M., Corcoran G., Lewis J., et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005, 40:1770-1776.
75. Catanzaro A., Cloud G.A., Stevens D.A., et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007, 45:562-568.
76. Stevens D.A., Rendon A., Gaona-Flores V., et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007, 132:952-958.
77. Courtney R., Wexler D., Radwanski E., et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004, 57:218-222.
78. Courtney R., Radwanski E., Lim J., et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004, 48:804-808.
79. Lazarus H.M., Blumer J.L., Yanovicjh S., et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002, 42:395-402.
80. Saravolatz L.D., Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630-637.
81. Proia L.A., Tenorio A.R. Successful use of voriconazole for treatment of coccidioides meningitis. Antimicrob Agents Chemother 2004, 48:2341.
82. Prabhu R.M., Bonnell M., Currier B.L., et al. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004, 39:e74-e77.
83. Cortez K.J., Walsh T.J., Bennett J.E. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36:1619-1622.
84. Letscher-Bru V., Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003, 51:513-521.
85. Hsue G., Napier J.T., Prince R.A., et al. Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 2004, 54:292-294.
86. Antony S. Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. Clin Infect Dis 2004, 39:879-880.
87. Park D., Sohn J., Cheong H., et al. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. BMC Infect Dis 2006, 6:26.